SOUTH SAN FRANCISCO, Calif.—Five Prime Therapeutics Inc. presented at the recent 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, sharing new preclinical data that demonstrate the potent antitumor activity of FPT155, its novel therapeutic CD80-Fc fusion protein. FPT155 was designed as a co-stimulatory molecule meant to stimulate T cell activation and break tumor immune tolerance. In in-vitro studies, the compound has induced T cell activation and cytokine production via CD28.